Evidence map›Paper›PMID 42131576›Full record

ArticleFrontiers in toxicology2026

A new

Pralhad Wangikar, Sara Cherradi, Pradhnya Choudhari, Aditi Wangikar, Vaibhav Madiwal, Salomé Roux, Nisha Banerjee, Pranav Panzade, Pallavi Gangarde, Nithish Kannan and 1 more

Abstract read
In one paragraph

Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pralhad WangikarPRADO Pvt Ltd, Pune, India.
Sara CherradiPredictCan Biotechnologies, Biopôle Euromédecine, Cap Sigma, Grabels, France.
Pradhnya ChoudhariPRADO Pvt Ltd, Pune, India.
Aditi WangikarPRADO Pvt Ltd, Pune, India.
Vaibhav MadiwalPRADO Pvt Ltd, Pune, India.
Salomé RouxPredictCan Biotechnologies, Biopôle Euromédecine, Cap Sigma, Grabels, France.
Nisha BanerjeePRADO Pvt Ltd, Pune, India.
Pranav PanzadePRADO Pvt Ltd, Pune, India.
Pallavi GangardePRADO Pvt Ltd, Pune, India.
Nithish KannanPRADO Pvt Ltd, Pune, India.
Hong Tuan DuongPredictCan Biotechnologies, Biopôle Euromédecine, Cap Sigma, Grabels, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury (DILI) is a major cause of drug development failure and market withdrawal. Despite the use of animal and human-derived preclinical models, none reliably predict human hepatotoxicity. Conventional animal studies, based on group-level averages, overlook inter-individual variability critical to idiosyncratic DILI. Although several alternatives to animal testing are available, implementation of alternative methodologies into safety evaluations is very slow and to date, no standalone validated alternative models to assess systemic toxicity exist. To address this, we developed a novel serum-educated rat liver spheroid model that captures individual metabolic diversity, allowing DILI to be assessed both

Indexed as

drug-induced liver injuryindividual variabilityIn vitro-in vivo correlationreduction of animal useserum-educated rat liver spheroid model

Identifiers

PMID42131576
PMCPMC13160669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.